Evangelos Terpos mainly investigates Internal medicine, Multiple myeloma, Bone disease, Bortezomib and Surgery. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Oncology. His Multiple myeloma study incorporates themes from Cancer research, Clinical trial, Zoledronic acid, Radiology and Osteonecrosis of the jaw.
His study explores the link between Bone disease and topics such as Osteolysis that cross with problems in N-terminal telopeptide. He interconnects Melphalan and Lenalidomide, Dexamethasone in the investigation of issues within Bortezomib. His studies deal with areas such as Bisphosphonate and Thalidomide as well as Surgery.
Evangelos Terpos mostly deals with Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery. The study incorporates disciplines such as Gastroenterology and Endocrinology in addition to Internal medicine. His Multiple myeloma research includes themes of Cancer research, Bone disease and Bone marrow.
His work in the fields of Oncology, such as Zoledronic acid, intersects with other areas such as In patient. His Bortezomib research incorporates themes from Proteasome inhibitor, Pharmacology and Renal function. His research in Surgery tackles topics such as Urology which are related to areas like Creatinine.
His primary scientific interests are in Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide. His Multiple myeloma research incorporates elements of Cancer research, Clinical trial, Bone disease and Bone marrow. His research on Clinical trial also deals with topics like
Hematology is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine. His biological study spans a wide range of topics, including Ixazomib, Relapsed refractory, Refractory and Pomalidomide. His work carried out in the field of Lenalidomide brings together such families of science as Prospective cohort study, Adverse effect and Thalidomide.
His primary areas of study are Internal medicine, Multiple myeloma, Oncology, Bortezomib and Clinical trial. In his work, AL amyloidosis is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine. The Multiple myeloma study combines topics in areas such as Minimal residual disease, Bone disease, Disease and Intensive care medicine.
In his research, Cancer research is intimately related to RANKL, which falls under the overarching field of Bone disease. Evangelos Terpos has researched Bortezomib in several fields, including Refractory and Transplantation. His Clinical trial research is multidisciplinary, incorporating perspectives in Salvage therapy and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn.
Hematological findings and complications of COVID-19.
Evangelos Terpos;Ioannis Ntanasis‐Stathopoulos;Ismail Elalamy;Efstathios Kastritis.
American Journal of Hematology (2020)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
M. A. Dimopoulos;E. Kastritis;C. Bamia;I. Melakopoulos.
Annals of Oncology (2008)
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
Evangelos Terpos;Evangelos Terpos;Richard Szydlo;Richard Szydlo;Jane F. Apperley;Jane F. Apperley;Evdoxia Hatjiharissi;Evdoxia Hatjiharissi.
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Meletios A. Dimopoulos;Evangelos Terpos;Asher Chanan-Khan;Nelson Leung.
Journal of Clinical Oncology (2010)
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid
Meletios A Dimopoulos;Efstathios Kastritis;Athanasios Anagnostopoulos;Ioannis Melakopoulos.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: